The round was led by Domain Associates. Existing investors participated, including Vulcan Capital, Canaan Partners, PolyTechnos Venture-Partners, Asset Management Company and Quantum Technology Partners.
BiPar said Jesse Treu, a partner at Domain Associates, and Wende Hutton, a venture partner at Canaan Partners, have joined the board of directors.
From the statement:
BiPar is developing multiple compounds designed to inhibit PARP 1 (poly-ADP-ribose polymerase), an enzyme that is crucial to cell repair and upregulated in certain tumors. The round fully funds the Company’s robust Phase 2 program for its lead drug candidate, BSI-201, and accelerates development of two additional drug candidates from BiPar’s pipeline.